A phase IV study of homoharringtonine, cytarabine, aclacinomycin and G-CSF (HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients#br#
网络出版日期: 2017-09-28
基金资助
National Natural Science Foundation of China(81270621, 81300451); National Public Health Grand Research Foundation(201202003); Shanghai Health System Advanced and Appropriate Technology Promotion Projects(2013SY001); Multiple Clinical Research Center Program of Shanghai Jiao Tong University School of Medicine (DLY201513).
A phase IV study of homoharringtonine, cytarabine, aclacinomycin and G-CSF (HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients
Online published: 2017-09-28
Supported by
National Natural Science Foundation of China(81270621, 81300451); National Public Health Grand Research Foundation(201202003); Shanghai Health System Advanced and Appropriate Technology Promotion Projects(2013SY001); Multiple Clinical Research Center Program of Shanghai Jiao Tong University School of Medicine (DLY201513).
LIU Zhao*, ZHANG Yun-xiang*, WANG Li-ning*, XIA Zheng, MAO Yuan-fei, ZHAO Hui-ji . A phase IV study of homoharringtonine, cytarabine, aclacinomycin and G-CSF (HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients#br#[J]. 上海交通大学学报(医学版), 2017 , 37(8) : 1100 . DOI: 10.3969/j.issn.1674-8115.2017.08.010
/
〈 |
|
〉 |